TROP2-targeting monoclonal antibody linked via a cleavable linker to a topoisomerase I inhibitor payload. Binding to TROP2 on tumor cells triggers internalization and intracellular release of the payload, which inhibits topoisomerase I to induce DNA damage and replication stress, leading to apoptosis, with potential bystander killing of adjacent tumor cells.